PhD position on functional valdidation of druggable targets

 Universität Würzburg  97080 Würzburg
The Comprehensive Cancer Center Mainfranken of the University of Würzburg in the program „Molecular Targets and Biomarkers“ offers a PhD position to a highly motivated young scientist to validate novel druggable Notch targets in multiple myeloma. The Comprehensive Cancer Center Mainfranken is internationally recognized for the excellent treatment of tumor diseases in the oncological center of the university hospital Würzburg. The position is funded by the Interdisciplinary Center for Clinical Research, University of Würzburg.
Multiple Myeloma (MM) is the second most common hematopoietic neoplasia characterized by growth of malignant plasma cells in the bone marrow and osteolytic bone disease. Notch is a survival factor of MM cells and is involved in specific MM cell-stroma interactions. The PhD candidate will screen for and validate cancer-specific RNA with the goal to identify targets for the treatment of multiple myeloma. High-throughput functional shRNA screening technology will be used for functional validation. Identified target genes will be screened for functional executors of a melphalan drug resistance phenotype of MM cells with high Notch activity. The applicant will perform this project in close collaboration with Martin Eilers´s group (Theodor Boveri Institut, University of Würzburg).
Applicants must have a master in biology, biomedicine, biochemistry or related discipline and will be integrated into the program of the Graduate School of Life Sciences at the University of Würzburg. Applications (including CV and references) should be submitted via e-mail to Prof. Franziska Jundt (jundt_f@ukw.de).
The University of Würzburg is an equal opportunities employer and places particular emphasis on fostering career opportunities for women, who are strongly encouraged to apply. Applications of disabled persons with equal qualifications will be treated preferentially.

References
1. Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, Jamin Y, Thway K, Robinson SP, Roels F, Witt O, Fischer M, Chesler L, Eilers M. Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. Cancer Cell. 2016 Aug 8;30(2):357-358.
2. Jung LA, Gebhardt A, Koelmel W, Ade CP, Walz S, Kuper J, von Eyss B, Letschert S, Redel C, d'Artista L, Biankin A, Zender L, Sauer M, Wolf E, Evan G, Kisker C, Eilers M. OmoMYC blunts promoter invasion of oncogenic MYC to inhibitr gene expression characteristic of MYC-dependent tumors. Oncogene. 2016 Oct 17. doi: 10.1038/onc.2016.354.
3. Schwarzer R, Nickel N, Godau J, Willie BM, Duda GN, Schwarzer R, Cirovic B, Leutz A, Manz R, Bogen B, Dörken B, Jundt F. Notch pathway inhibition controls myleoma bone disease in the murine MOPC315.BM model. Blood Cancer J. 2014 Jun 13;4:e217. doi: 10.1038/bcj.2014.37.
4. Schwarzer R, Dörken B, Jundt F. Notch is an essential upstream regulator of NF-kB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia.2012 Apr;26(4):806-13. doi: 10.1038/leu.2011.265.
 
How to apply:
Applications (including CV and references) should be submitted via e-mail to Prof. Franziska Jundt (jundt_f@ukw.de)
Send application to
Univ.-Prof. Dr. med. Franziska Jundt
Universitätsklinikum Würzburg
Medizinische Klinik und Poliklinik II
Oberdürrbacher Straße 6
97080 Würzburg
While applying for the job please refer to jobvector

About Universität Würzburg

University Hospital Würzburg

More about Universität Würzburg

Get jobs on a daily basis for free

Keywords:
Filters: